Paper Details

  1. Home
  2. Paper Details

Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma.

Author: BohliusJulia, BrillantCorinne, EngertAndreas, HerbstChristine, MonsefIna, RehanFareed Ahmed, SchulzHolger, SkoetzNicole, SpechtLena

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

While combined chemotherapy and radiation therapy (CMT) is the standard treatment for early-stage Hodgkin lymphoma (HL), the role of radiation is being questioned due to long-term side effects like secondary cancers. Some studies suggest that chemotherapy alone may be sufficient for this stage of the disease.
Paper Details　
Original Abstract of the Article :
Combined modality treatment (CMT) consisting of chemotherapy followed by localised radiotherapy is standard treatment for patients with early stage Hodgkin lymphoma (HL). However, due to long term adverse effects such as secondary malignancies, the role of radiotherapy has been questioned recently a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD007110.pub2

データ提供：米国国立医学図書館（NLM）

Chemotherapy vs. Combined Modality Treatment for Early Stage Hodgkin Lymphoma: A Debate Continues

This research examines the ongoing debate surrounding the optimal treatment strategy for [early stage Hodgkin lymphoma (HL)]. The authors explore the potential benefits and drawbacks of [combined modality treatment (CMT)], which involves [chemotherapy] followed by [localised radiotherapy], compared to [chemotherapy alone]. The study highlights the concerns regarding [long term adverse effects] associated with [radiotherapy] while acknowledging the need for further research to determine the most effective and safe treatment approach for [early stage HL].

Finding the Right Path for Hodgkin Lymphoma Treatment: A Balancing Act

The study underscores the complexities of [Hodgkin lymphoma (HL)] treatment, highlighting the ongoing debate between [chemotherapy alone] and [combined modality treatment (CMT)]. The researchers present a balanced perspective, recognizing the potential benefits and drawbacks of each approach. This research emphasizes the need for careful consideration of individual patient factors and the importance of continued research to optimize [HL] treatment strategies.

Hodgkin Lymphoma: Navigating a Delicate Path to Recovery

This research offers valuable insights into the challenging landscape of [Hodgkin lymphoma (HL)] treatment. It emphasizes the need for individualized care and careful consideration of both the potential benefits and risks of different treatment options. The study highlights the ongoing debate surrounding the optimal approach for [early stage HL], suggesting that further research is needed to develop more effective and safe therapies.

Dr.Camel's Conclusion

The desert of [Hodgkin lymphoma (HL)] treatment can be a complex and uncertain journey. This research highlights the ongoing quest to find the most effective and safe path to recovery for patients. It's a reminder that we need to carefully consider all the factors involved in treatment decisions and embrace the ongoing pursuit of improved therapies for [HL].

Date :
  1. Date Completed 2011-03-23
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

21328291

DOI: Digital Object Identifier

10.1002/14651858.CD007110.pub2

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.